振东制药
(300158)
| 流通市值：42.09亿 | | | 总市值：42.23亿 |
| 流通股本：10.24亿 | | | 总股本：10.27亿 |
| 报告期 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 2,783,745,444.64 | 1,932,888,842.05 | 951,417,159.09 | 3,728,555,341.19 |
| 营业收入 | 2,783,745,444.64 | 1,932,888,842.05 | 951,417,159.09 | 3,728,555,341.19 |
| 二、营业总成本 | 2,795,510,880.16 | 1,921,339,890.75 | 977,786,837.89 | 3,922,191,930.94 |
| 营业成本 | 1,369,609,399.07 | 982,899,322.05 | 504,388,014.12 | 1,889,841,963.93 |
| 税金及附加 | 25,341,313.03 | 18,204,705.4 | 9,493,817.83 | 35,789,125.34 |
| 销售费用 | 1,072,756,701.01 | 715,645,260.43 | 366,020,942.78 | 1,517,555,525.96 |
| 管理费用 | 198,355,911.4 | 122,550,337.59 | 49,970,886.18 | 290,910,183.03 |
| 研发费用 | 137,283,367.79 | 88,740,206.71 | 48,885,568.66 | 178,107,392.51 |
| 财务费用 | -7,835,812.14 | -6,699,941.43 | -972,391.69 | 9,987,740.17 |
| 其中:利息费用 | 998,651.59 | 941,615.42 | 464,082.28 | 13,732,821.43 |
| 其中:利息收入 | 9,983,177.65 | 7,911,421.34 | 1,815,727.9 | 6,236,081.01 |
| 加:公允价值变动收益 | 3,634,684.17 | 4,663,843.67 | 3,953,915.3 | 11,590,994.48 |
| 加:投资收益 | 23,736,148.67 | 16,934,567.39 | 9,782,844.63 | 54,458,971.77 |
| 资产处置收益 | 192,609.6 | 170,147.6 | 83,377.91 | -320,481.39 |
| 资产减值损失(新) | -15,770,230.63 | -10,858,154.25 | 7,792.54 | -5,252,582.7 |
| 信用减值损失(新) | -21,635,427.84 | -22,035,634.53 | -1,723,445.72 | 46,151,417.42 |
| 其他收益 | 33,345,000.05 | 28,158,427.79 | 21,569,422.97 | 81,087,881.56 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 11,737,348.5 | 28,582,148.97 | 7,304,228.83 | -5,920,388.61 |
| 加:营业外收入 | 2,071,303.72 | 1,647,408.38 | 537,318.51 | 4,376,988.06 |
| 减:营业外支出 | 2,651,262.92 | 739,515.24 | 399,436.61 | 3,737,077.96 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 11,157,389.3 | 29,490,042.11 | 7,442,110.73 | -5,280,478.51 |
| 减:所得税费用 | 15,291,462.89 | 17,280,721.86 | 8,344,176.63 | 51,718,365.2 |
| 六、净利润 | -4,134,073.59 | 12,209,320.25 | -902,065.9 | -56,998,843.71 |
| 持续经营净利润 | -4,134,073.59 | 12,209,320.25 | -902,065.9 | -56,998,843.71 |
| 归属于母公司股东的净利润 | -874,204.92 | 14,542,410.37 | -394,728.53 | -51,290,041.06 |
| 少数股东损益 | -3,259,868.67 | -2,333,090.12 | -507,337.37 | -5,708,802.65 |
| (一)基本每股收益 | 0 | 0.01 | 0 | -0.05 |
| (二)稀释每股收益 | 0 | 0.01 | 0 | -0.05 |
| 八、其他综合收益 | -31,342,821.29 | -31,335,731.08 | 10,584.54 | 74,152.07 |
| 归属于母公司股东的其他综合收益 | -31,342,821.29 | -31,335,731.08 | 10,584.54 | 74,152.07 |
| 九、综合收益总额 | -35,476,894.88 | -19,126,410.83 | -891,481.36 | -56,924,691.64 |
| 归属于母公司股东的综合收益总额 | -32,217,026.21 | -16,793,320.71 | -384,143.99 | -51,215,888.99 |
| 归属于少数股东的综合收益总额 | -3,259,868.67 | -2,333,090.12 | -507,337.37 | -5,708,802.65 |
| 公告日期 | 2023-10-23 | 2023-08-31 | 2023-04-25 | 2023-04-25 |
| 审计意见(境内) | | | | 标准无保留意见 |